Search the Newsreel

Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Analysts

Eleven analysts have given Alto Neuroscience, Inc. (NYSE:ANRO) a consensus "Moderate Buy" rating, with eight recommending a buy, two a sell, and one a hold. The average 12-month price target is $35.25, significantly higher than its opening price of $27.09. Despite increased institutional investment …

ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates

ClearPoint Neuro, Inc. (CLPT) reported a Q2 loss of $0.38 per share, missing the Zacks Consensus Estimate of a $0.29 loss, and revenues of $10.88 million, falling short of estimates by 16.31%. The company's shares have gained 9.2% year-to-date, slightly underperforming the S&P 500. …

Minerva Neurosciences (NERV) awards options tied to Phase 3 trial

Minerva Neurosciences (NERV) reported the grant of 12,147 stock options to director Inderjit Kaul, with an exercise price of $3.97 and an expiration date of August 2, 2036. The options' vesting is performance- and time-based, with significant portions contingent on the success of a …

Form 4 Minerva Neurosciences Inc For: 3 August By Investing.com

This article announces the filing of a Form 4 for Minerva Neurosciences Inc. on August 3rd. It indicates that this is an insider trading report, suggesting that company insiders have bought or sold shares. The article also provides the stock's current performance (NERV +2.02%).

ClearPoint Neuro Q2 Earnings Call Highlights

ClearPoint Neuro (CLPT) reported an 18% revenue growth in Q2 2026, reaching $10.9 million, and adjusted its full-year guidance to $48-$52 million. The company is shifting investment priorities towards clinical capacity, preclinical laboratory services, and neuro drug delivery technologies, with increased spending in R&D, …

ProMIS Neurosciences to report Q2 results, host investor call and webcast

ProMIS Neurosciences will release its Q2 results for the period ending June 30, 2026, on August 13, 2026. The company will also host an investor conference call and webcast on the same day at 4:30 p.m. ET to discuss the results. This news brief …

ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings

ClearPoint Neuro, Inc. (CLPT) reported its Q2 2026 earnings, missing analyst expectations for both EPS and revenue. The company's cash reserves decreased, and it lowered its full-year 2026 revenue guidance to $48 million to $52 million. This performance is attributed to a pivot towards …

ClearPoint Neuro Reports Second Quarter 2026 Results

ClearPoint Neuro, Inc. announced its second-quarter 2026 financial results, reporting $10.9 million in revenue, an 18% increase year-over-year, driven by the IRRA flow Portfolio acquisition and growth in neurosurgery navigation. While Biologics and Drug Delivery revenue saw a decline, the company expects a rebound …

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

ProMIS Neurosciences Inc. will report its second-quarter 2026 financial results and provide a corporate update on August 13, 2026. The company will host an investor conference call and webcast on the same day at 4:30 p.m. ET to discuss these results and updates. ProMIS …

Canaccord raises Neurocrine Bio price target on strong sales beat

Canaccord Genuity increased its price target for Neurocrine Biosciences Inc. (NASDAQ: NBIX) from $200 to $210, maintaining a Buy rating, following the company's strong second-quarter performance. Neurocrine's sales for Ingrezza and Crenessity significantly exceeded analyst estimates, contributing to a 34% revenue growth. The company …

(CLPT) as a Liquidity Pulse for Institutional Tactics

Clearpoint Neuro, Inc. (NASDAQ: CLPT) is experiencing strong near-term sentiment that is challenging persistent mid and long-term weakness. The article details institutional trading strategies including position, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis, indicating potential resistance and support levels. An exceptional 117.8:1 …

Jupiter Neurosciences expands into psychedelics with $100m deal

Jupiter Neurosciences has acquired exclusive US rights to ALA-002, a clinical-stage psychedelic therapy candidate, for up to $100 million, marking its expansion into neuropsychiatric disorders. This move adds a second clinical program to Jupiter's portfolio, alongside therapies for Parkinson's disease, and signals a broader …

NeuroOne(R) to Report Third Quarter Fiscal Year 2026 Financial Results on Thursday, August 13, 2026, at 8:30 a.m. Eastern Time

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced it will release its fiscal third quarter financial results for the period ended June 30, 2026, before market open on August 13, 2026. The company will host an investor conference call and webcast on the same day …

H.C. Wainwright reiterates Neurocrine Bio stock rating on pipeline progress By Investing.com

H.C. Wainwright has reaffirmed its Buy rating and $215.00 price target for Neurocrine Biosciences Inc. (NASDAQ: NBIX), citing the company's strong pipeline progress and financial performance. The company reported significant revenue growth and provided updates on its clinical trials for osavampator and direclidine, which …

NERV Q2'26 Earnings: EPS estimate is (0.19) USD

Minerva Neurosciences, Inc (NERV) is projected to announce its Q2'26 earnings on August 4, 2026, with an estimated revenue of $0 and an EPS of ($0.19). This article provides a brief overview of the upcoming financial disclosure, including historical and estimated revenue and EPS …

Contineum Therapeutics CEO Carmine Stengone disposes of shares worth $40,029

Contineum Therapeutics CEO Carmine N. Stengone sold 2,500 Class A common shares for $16.01 each on August 3, 2026, totaling $40,029. On the same day, he acquired 2,500 shares via option exercise at $1.01 per share. This transaction resulted in a decrease in his …

Aeroflex Neu Ltd FY26 Profit Jumps to ₹1.75 Cr; Eyes Diversification

Neueon Corporation narrows Q1FY27 standalone loss to ₹82.11 lakh

ClearPoint Neuro (NASDAQ:CLPT) Issues Quarterly Earnings Results, Misses Estimates By $0.09 EPS

ClearPoint Neuro (Nasdaq: CLPT) lifts Q2 2026 revenue while net loss deepens

Contineum Therapeutics, Inc. $CTNM Position Increased by Janus Henderson Group PLC

Aeroflex Neu FY26 Results: Net profit surges 660% to ₹175 lakh

Is Neurocrine Biosciences (NBIX) A Bargain After Strong Q2 Results And Higher Guidance?

Neurocrine Biosciences (NBIX) reported strong Q2 2026 results and raised full-year INGREZZA sales guidance, yet its share price declined by about 10% on the day of the announcement, despite positive longer-term momentum. The stock is currently valued at $166.80, considered 13.5% undervalued by Simply …

Jupiter Neurosciences (JUNS) Stock Forecast & Analyst Ratings

This article provides a stock forecast and analyst ratings for Jupiter Neurosciences (JUNS). It likely covers aspects such as price targets, current recommendations from analysts, and potential future performance. Investors can use this information to inform their decisions regarding the stock.

Perceptive Advisors LLC Takes $9.95 Million Position in Neumora Therapeutics, Inc. $NMRA

Perceptive Advisors LLC has acquired a significant stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA), purchasing over 5.1 million shares valued at approximately $9.95 million. This investment represents about 2.75% of the company, contributing to the 47.65% institutional ownership of Neumora Therapeutics. While analyst sentiment is …

889,254 Shares in Minerva Neurosciences, Inc $NERV Bought by DV Trading LLC

Perceptive Advisors LLC Has $16.40 Million Stake in Contineum Therapeutics, Inc. $CTNM

Seven Fleet Capital Management LP Makes New Investment in Minerva Neurosciences, Inc $NERV

Neueon Corporation Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

NewMarket Corporation Reports Second Quarter and First Half 2026 Results

NewMarket Corporation reported strong financial results for the second quarter and first half of 2026, with net income increasing to $133.8 million for Q2 2026 and $251.8 million for H1 2026. The petroleum additives segment saw improved operating profit due to surcharges addressing higher …

Neuronetics’ Five New Hires Get RSUs Vesting Over 4 Years

Neuronetics (NASDAQ: STIM) has granted equity inducement awards in the form of restricted stock units (RSUs) to five new non-executive employees. These awards, made under the company's 2020 Inducement Incentive Plan and in accordance with Nasdaq Listing Rule 5635(c)(4), vest over three to four …

PMN|ProMIS Neurosciences Inc|Price:13.720|Chg%:-1.200

This article provides a comprehensive stock analysis of ProMIS Neurosciences Inc (PMN), highlighting its strong fundamentals and high growth potential. The company's valuation is considered fair, and institutional ownership is notably high. Analysts have issued "Buy" ratings, projecting a significant upside for the stock …

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Alnylam Pharma (ALNY) and Fortrea Holdings Inc. (FTRE)

This article summarizes recent analyst ratings for three healthcare companies: Bicycle Therapeutics (BCYC), Alnylam Pharma (ALNY), and Fortrea Holdings Inc. (FTRE). Needham maintained a Buy rating for Bicycle Therapeutics, William Blair maintained a Buy for Alnylam Pharma, and Bank of America Securities maintained a …

Neurocrine Biosciences (NBIX) Is Down 5.1% After Q2 Earnings Beat And Higher INGREZZA Guidance – What's Changed

In the second quarter of 2026, Neurocrine Biosciences reported revenue of US$959.0 million and net income of US$144.4 million, sharply higher than a year earlier and ahead of analyst expectations, with INGREZZA, CRENESSITY, and newly acquired VYKAT XR leading record sales. The company also …

Neurocrine Biosciences (NBIX) Appoints Four Senior Leaders As Pipeline And Portfolio Expand

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Neurocrine Biosciences appointed a new Chief Business Officer and three Senior Vice Presidents to its senior leadership team. The moves come as the company …

RBC Capital Keeps Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM)